For people with vitiligo and their caregivers
What this page helps you do
The current guideline reviewed by SteadySkin does not establish pseudocatalase as standard vitiligo care. We do not publish a product-specific efficacy conclusion without exact full-text review. Claims involving ultraviolet light need extra caution.
- Your task
- Separate what the evidence supports from what it does not establish for an individual.
- The clinician boundary
- Diagnosis, assessment of activity and body sites, prescribing, monitoring, and personalized treatment decisions belong to a qualified clinician.
Is pseudocatalase established vitiligo care?
The current British guideline reviewed by SteadySkin does not establish pseudocatalase as standard vitiligo care. That does not prove that every past or future formulation is ineffective; it means this page should not present the approach as established treatment. Evidence
What is known
The guideline evaluates established management choices and evidence limits. SteadySkin has not completed an exact-full-text review that supports a product-specific efficacy claim. We do not summarize one from an abstract, seller page, or testimonial.
What is uncertain
Products sharing the name may differ. The name alone does not establish that a current product matches a studied preparation, has reliable manufacturing, or produces a clinical benefit.
What if the claim also involves ultraviolet light?
Do not turn a pseudocatalase claim into a self-directed ultraviolet plan. Narrowband UVB remains clinician-directed care. A cream or seller claim does not establish a safe device, schedule, application sequence, or monitoring plan. Evidence Evidence
What is known
Current phototherapy guidance separates clinician-directed medical treatment from unsupervised ultraviolet exposure and requires condition-specific precautions and oversight.
What is uncertain
Without exact full-text and product review, SteadySkin cannot establish whether a seller’s combined claim matches any studied intervention or how it should affect an individual plan.
Evidence and update context
This optional layer shows the evidence boundary reviewed for this page as of 2026-08-03.
- What this evidence supports
- The guideline evaluates established management choices and evidence limits. SteadySkin has not completed an exact-full-text review that supports a product-specific efficacy claim. We do not summarize one from an abstract, seller page, or testimonial.
- What it does not establish
- Products sharing the name may differ. The name alone does not establish that a current product matches a studied preparation, has reliable manufacturing, or produces a clinical benefit.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
Do not turn a pseudocatalase claim into a self-directed ultraviolet plan. Narrowband UVB remains clinician-directed care. A cream or seller claim does not establish a safe device, schedule, application sequence, or monitoring plan.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-01-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Goulden V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-09-01
- SteadySkin last checked
- 2026-07-29
What this source can and cannot tell you
What this source supports
It supports that traditional NB-UVB fluorescent lamps emit a narrow UVB band peaking around 311 nanometres, plus clinical uses, comparisons with other ultraviolet treatments, and safety boundaries including sunburn-type reactions.
What it does not support
It does not provide a personal treatment plan or establish any home-use setting. SteadySkin never reproduces its treatment schedules.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.